Invex Therapeutics Calls General Meeting to Vote on Tattarang Group Stake Rise to 41.57%

Aditi Sarkar

04 November 2026 12:28 PM AEDT

Invex Therapeutics Calls General Meeting to Vote on Tattarang Group Stake Rise to 41.57%

Image Source: Krish Capital Pty Ltd

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Invex Therapeutics Ltd (ASX:IXC) has notified shareholders of a General Meeting to be held on 4 December 2026 at Level 3, 101 St Georges Terrace, Perth WA 6000, at 10.00am AWST, at which shareholders will vote on resolutions that would increase the Tattarang Group's voting power in the company from 10.24% to up to 41.57%.

Key Points

General Meeting scheduled for 4 December 2026 at 10.00am AWST in Perth, Western Australia
Independent Expert Moore Australia Corporate Finance (WA) Pty Ltd determined the transactions subject to Resolutions 1 and 2 are NOT FAIR BUT REASONABLE to non-associated shareholders
Resolution 1 seeks Section 611 approval for the Tattarang Group, including John Andrew Henry Forrest and Nicola Margaret Forrest, to increase voting power from 10.24% to up to 41.57%
Resolution 2 seeks approval to acquire 176,261 fully paid ordinary shares in Rekover Therapeutics Limited from Tenmile Ventures Pty Ltd under Listing Rule 10.1
Eligible voters are shareholders registered at 4:00pm WST on 2 December 2026

Tattarang Group Stake Increase and Securities Issuance

Resolution 1 seeks shareholder approval under Section 611 (item 7) of the Corporations Act for the company to issue securities to Tenmile Ventures Pty Ltd (ACN 657 117 130). The proposed securities include 14,310,100 Consideration Shares under a Share Purchase Agreement, up to 56,250,000 Placement Shares, 29,017,704 Performance Rights and up to 29,017,704 shares on conversion, and 9,500,000 Tenmile Options and up to 9,500,000 shares on exercise. The resolution is subject to the passing of each of the other Essential Resolutions, and a voting prohibition statement applies to this resolution.

Acquisition of Rekover Therapeutics Shares Under Listing Rule 10.1

Resolution 2 seeks approval under ASX Listing Rule 10.1 for the company to acquire 176,261 fully paid ordinary shares in Rekover Therapeutics Limited (NZBN 9429047918009) from Tenmile Ventures Pty Ltd, described in the filing as an associate of a substantial holder of the company holding 10% or more. The Independent Expert's Report, prepared by Moore Australia Corporate Finance (WA) Pty Ltd, assessed the fairness and reasonableness of the transactions subject to both Resolutions 1 and 2, concluding they are not fair but reasonable to non-associated shareholders.

Consideration Securities Issuance to Other Vendors

Resolution 3 seeks approval under Listing Rule 7.1 for the company to issue up to 30,689,900 shares and 62,232,296 Performance Rights to vendors other than Tenmile Ventures Pty Ltd, or their nominees, on terms set out in the Explanatory Statement. This resolution is also subject to the passing of each of the other Essential Resolutions, and a voting exclusion statement applies. The company's authorised release was signed by Company Secretary Tim Slate. The Notice of Meeting and Explanatory Memorandum are available on the company's ASX market announcements platform.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.